Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction.
heart failure
natriuretic peptides
outcomes
Journal
Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365
Informations de publication
Date de publication:
03 09 2019
03 09 2019
Historique:
received:
26
01
2019
revised:
12
06
2019
accepted:
17
06
2019
entrez:
31
8
2019
pubmed:
31
8
2019
medline:
15
5
2020
Statut:
ppublish
Résumé
The GUIDE-IT (GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure) trial demonstrated that a strategy to "guide" application of guideline-directed medical therapy (GDMT) by reducing amino-terminal pro-B-type natriuretic peptide (NT-proBNP) was not superior to GDMT alone. The purpose of this study was to examine the prognostic meaning of NT-proBNP changes following heart failure (HF) therapy intensification relative to the goal NT-proBNP value of 1,000 pg/ml explored in the GUIDE-IT trial. A total of 638 study participants were included who were alive and had available NT-proBNP results 90 days after randomization. Rates of subsequent cardiovascular (CV) death/HF hospitalization or all-cause mortality during follow-up and Kansas City Cardiomyopathy Questionnaire (KCCQ) overall scores were analyzed. A total of 198 (31.0%) subjects had an NT-proBNP ≤1,000 pg/ml at 90 days with no difference in achievement of NT-proBNP goal between the biomarker-guided and usual care arms. NT-proBNP ≤1,000 pg/ml by 90 days was associated with longer freedom from CV/HF hospitalization or all-cause mortality (p < 0.001 for both) and lower adjusted hazard of subsequent HF hospitalization/CV death (hazard ratio: 0.26; 95% confidence interval: 0.15 to 0.46; p < 0.001) and all-cause mortality (hazard ratio: 0.34; 95% confidence interval: 0.15 to 0.77; p = 0.009). Regardless of elevated baseline concentration, an NT-proBNP ≤1,000 pg/ml at 90 days was associated with better outcomes and significantly better KCCQ overall scores (p = 0.02). Patients with heart failure with reduced ejection fraction whose NT-proBNP levels decreased to ≤1,000 pg/ml during GDMT had better outcomes. These findings may help to understand the results of the GUIDE-IT trial. (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment [GUIDE-IT]; NCT01685840).
Sections du résumé
BACKGROUND
The GUIDE-IT (GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure) trial demonstrated that a strategy to "guide" application of guideline-directed medical therapy (GDMT) by reducing amino-terminal pro-B-type natriuretic peptide (NT-proBNP) was not superior to GDMT alone.
OBJECTIVES
The purpose of this study was to examine the prognostic meaning of NT-proBNP changes following heart failure (HF) therapy intensification relative to the goal NT-proBNP value of 1,000 pg/ml explored in the GUIDE-IT trial.
METHODS
A total of 638 study participants were included who were alive and had available NT-proBNP results 90 days after randomization. Rates of subsequent cardiovascular (CV) death/HF hospitalization or all-cause mortality during follow-up and Kansas City Cardiomyopathy Questionnaire (KCCQ) overall scores were analyzed.
RESULTS
A total of 198 (31.0%) subjects had an NT-proBNP ≤1,000 pg/ml at 90 days with no difference in achievement of NT-proBNP goal between the biomarker-guided and usual care arms. NT-proBNP ≤1,000 pg/ml by 90 days was associated with longer freedom from CV/HF hospitalization or all-cause mortality (p < 0.001 for both) and lower adjusted hazard of subsequent HF hospitalization/CV death (hazard ratio: 0.26; 95% confidence interval: 0.15 to 0.46; p < 0.001) and all-cause mortality (hazard ratio: 0.34; 95% confidence interval: 0.15 to 0.77; p = 0.009). Regardless of elevated baseline concentration, an NT-proBNP ≤1,000 pg/ml at 90 days was associated with better outcomes and significantly better KCCQ overall scores (p = 0.02).
CONCLUSIONS
Patients with heart failure with reduced ejection fraction whose NT-proBNP levels decreased to ≤1,000 pg/ml during GDMT had better outcomes. These findings may help to understand the results of the GUIDE-IT trial. (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment [GUIDE-IT]; NCT01685840).
Identifiants
pubmed: 31466618
pii: S0735-1097(19)35785-7
doi: 10.1016/j.jacc.2019.06.055
pmc: PMC6719723
mid: NIHMS1534169
pii:
doi:
Substances chimiques
Biomarkers
0
Peptide Fragments
0
pro-brain natriuretic peptide (1-76)
0
Natriuretic Peptide, Brain
114471-18-0
Banques de données
ClinicalTrials.gov
['NCT01685840']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1205-1217Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL105448
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL105451
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL105457
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Références
Congest Heart Fail. 2013 May-Jun;19(3):135-42
pubmed: 23279139
J Am Coll Cardiol. 2017 Aug 8;70(6):776-803
pubmed: 28461007
Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):3-11
pubmed: 29490032
Am Heart J. 2012 Nov;164(5):793-799.e1
pubmed: 23137512
J Am Coll Cardiol. 2011 Oct 25;58(18):1881-9
pubmed: 22018299
J Card Fail. 2011 Aug;17(8):622-5
pubmed: 21807322
Circ Cardiovasc Qual Outcomes. 2011 May;4(3):363-71
pubmed: 21586725
JACC Heart Fail. 2014 Oct;2(5):457-65
pubmed: 25194287
JAMA. 2017 Aug 22;318(8):713-720
pubmed: 28829876
Circ Heart Fail. 2013 Nov;6(6):1206-13
pubmed: 24114865
JACC Heart Fail. 2019 Feb;7(2):158-168
pubmed: 30611722
Eur J Heart Fail. 2009 Apr;11(4):367-77
pubmed: 19179406
JAMA. 2017 Aug 22;318(8):707-708
pubmed: 28829853
J Am Coll Cardiol. 2018 Jan 16;71(2):201-230
pubmed: 29277252
J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239
pubmed: 23747642
Am Heart J. 2018 May;199:130-136
pubmed: 29754651
Clin Pharmacol Ther. 2013 Jan;93(1):57-67
pubmed: 23187878
J Card Fail. 2015 Jan;21(1):9-15
pubmed: 25463415
Eur J Heart Fail. 2013 Mar;15(3):342-51
pubmed: 23132825
J Am Coll Cardiol. 2016 Dec 6;68(22):2425-2436
pubmed: 27908347